{
    "clinical_study": {
        "@rank": "107473", 
        "acronym": "BetaSleep", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "The study aims to investigate the relationship between sleep quality, quality of life,other\n      disorders and therapies in Multiple Sclerosis (MS) patients treated with Betaferon."
        }, 
        "brief_title": "Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients \u2265 18 years of age with relapsing remitting multiple sclerosis or a\n             clinically isolated syndrome and an expanded disability status scale score \u22645.\n\n          -  Patients must be on treatment with Betaferon and tolerate Betaferon according to the\n             investigator's evaluation, but should not have received Betaferon longer than six\n             months.\n\n          -  Written informed consent must be obtained\n\n        Exclusion Criteria:\n\n          -  Patients who do not tolerate Betaferon according to the investigator's evaluation or\n             have been treated with Betaferon for more than six months.\n\n          -  Patients receiving any other disease modifying drug or MS specific treatments\n\n          -  Contraindications of Betaferon described in the Summary of Product Characteristics."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population will consist of patients with relapsing remitting multiple sclerosis\n        (RRMS) or patients with a clinically isolated syndrome (CIS) with an Expanded Disability\n        Status Scale (EDSS) score \u22645 who tolerate Betaferon according to the investigator's\n        evaluation, but have not received Betaferon longer than six months. Participants will be\n        recruited from private neurological offices and neurology departments throughout Germany.\n\n        In this non-interventional observational study, the decision on the duration and dosage of\n        treatment is solely at the discretion of the attending physician.\n\n        The medication is prescribed at regular visits to the investigator's office. Commercially\n        available product will be used to treat the patients."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766063", 
            "org_study_id": "16352", 
            "secondary_id": "BF1212DE"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients will be followed-up for 24 months", 
            "intervention_name": "Interferon beta-1b (Betaferon, BAY 86-5046)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Interferons", 
                "Interferon beta-1b"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Sclerosis", 
            "Sleep", 
            "Quality of life", 
            "Observational study"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Germany"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon\u00ae Treated MS Patients", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Fatique assessed by the Modified Fatigue Impact Scale (MFIS)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766063"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Daytime sleepiness is measured with the Epworth Sleepiness Scale (ESS)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Depression and anxiety is measured with the Hospital anxiety and depression scale (HADS)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Pain is measured with the Hamburg Pain Adjective List (Hamburger Schmerz Adjektiv Liste (HSAL)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Severity of restless legs syndrome measured with the International Restless Legs Syndrome Study (IRLSS) group rating scale.", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Safety variables will be summarized using descriptive statistics based on adverse events collection", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}